Losartan

Generic Name: Losartan

Brand Names: Hyzaar, Cozaar

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃ClN_₆O

CAS Number: 114798-26-4

Unique Ingredient Identifier: JMS50MPO89

Background: Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication: Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions: Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Clinical Trials

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Melanoma
Advanced Solid Tumors

Interventions: Drug: losartan
Drug: rosuvastatin
Drug: bupropion immediate release (IR)
Drug: dextromethorphan
Drug: caffeine
Drug: modafinil
Drug: omeprazole
Drug: midazolam
Drug: encorafenib
Drug: binimetinib

First Posted Date: 2019-03-06

Last Posted Date: 2023-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 56

Registration Number: NCT03864042

Locations: 🇨🇦
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸
UC Irvine Health, Orange, California, United States
🇺🇸
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States

and more 26 locations

Losartan and Emotional Memory

Not Applicable

Completed

Conditions: Memory
Learning

Interventions: Other: placebo
Drug: Losartan Potassium

First Posted Date: 2018-12-04

Last Posted Date: 2018-12-06

Lead Sponsor: University of Oxford

Target Recruit Count: 53

Registration Number: NCT03763409

Locations: 🇬🇧
Department of Psychiatry, University of Oxford, Oxford, United Kingdom

Nighttime Losartan in Continous Ambulatory Peritoneal Dialysis (NVCAPD)

Phase 4

Conditions: Hypertension,Nephropathy

Interventions: Drug: Losartan

First Posted Date: 2018-10-02

Last Posted Date: 2018-11-05

Lead Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 68

Registration Number: NCT03692013

Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease

Phase 4

Completed

Conditions: Aortic Stenosis
Aortic Regurgitation
Hypertension
LVM
Left Ventricular Hypertrophy

Interventions: Drug: Amlodipine 5mg
Drug: Losartan
Drug: Losartan and Amlodipine
Drug: Amlodipine/Losartan/Chlorthalidone
Drug: current treatment

First Posted Date: 2018-09-11

Last Posted Date: 2022-09-15

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 128

Registration Number: NCT03666351

Locations: 🇰🇷
10 Institutions Including Asan Medical Center, Seoul, Korea, Republic of

Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI

Phase 2

Active, not recruiting

Conditions: Mucopolysaccharidosis IV A
Mucopolysaccharidoses
MPS IV A
MPS VI
Mucopolysaccharidosis VI
MPS - Mucopolysaccharidosis
Morquio A Syndrome
Morquio Syndrome A
Morquio Syndrome

Interventions: Drug: Losartan
Drug: Placebo

First Posted Date: 2018-08-15

Last Posted Date: 2022-12-19

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 10

Registration Number: NCT03632213

Locations: 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

Losartan/Amlodipine on Hemodynamics Parameters and Arterial Stiffness in Arterial Hypertension

Phase 4

Conditions: Hypertension

Interventions: Drug: Losartan and Amlodipine
Drug: Losartan

First Posted Date: 2018-08-10

Last Posted Date: 2018-08-17

Lead Sponsor: Centro Universitario de Ciencias de la Salud, Mexico

Target Recruit Count: 28

Registration Number: NCT03626259

Locations: 🇲🇽
Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico

Fixed-Free HTN Trial

Phase 4

Conditions: Hypertension

Interventions: Drug: Standard of care
Drug: Losartan and amlodipine and hydrochlorothiazide

First Posted Date: 2018-07-05

Last Posted Date: 2018-07-05

Lead Sponsor: Hotel Dieu de France Hospital

Target Recruit Count: 100

Registration Number: NCT03578042

Locations: 🇱🇧
Hotel Dieu de France Hospital, Beirut, Lebanon

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: FOLFIRINOX
Radiation: SBRT
Drug: Losartan
Procedure: Surgery
Drug: Nivolumab

First Posted Date: 2018-06-20

Last Posted Date: 2022-09-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 168

Registration Number: NCT03563248

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 7 locations